Physiomics PLC AIM Rule 26 Website Change (0359U)
26 Marzo 2019 - 7:00AM
UK Regulatory
TIDMPYC
RNS Number : 0359U
Physiomics PLC
26 March 2019
26(th) March 2019
Physiomics plc
("Physiomics") or ("the Company")
AIM Rule 26 Website Change
Physiomics updates its branding, website and URL to improve
customer experience
Physiomics plc (AIM: PYC), a provider of technology-based
solutions to predict the effects of cancer treatment regimens for
the biopharma industry, is pleased to announce it has undertaken an
exercise to "modernise and simplify" its online image in advance of
its attendance at the American Association for Cancer Research
Annual Meeting from 31(st) March. The Company has updated its logo
and web address as well as implemented significant changes to its
website intended to increase the amount and quality of information
available to potential clients and partners. The key changes and
their rationale are as follows:
-- Updating of Physiomics logo to give it a more modern look and
feel consistent with how we would like to be viewed by our
clients
-- Adoption of a new, simplified web address (or URL). From
today our URL will be www.physiomics.co.uk and the section
addressing AIM Rule 26 requirements will be
www.physiomics.co.uk/investors/
-- Upgrading of the Physiomics website introducing a number of new features including:
o Enhanced information about Physiomics' core business areas,
including fuller descriptions of the mechanics and benefits of our
proprietary Virtual Tumour(TM) technology
o Inclusion of more examples of past projects that showcase key
areas of experience and expertise
o Introduction of a dedicated section on Personalised Oncology
where for the first time we outline our work in this area on our
website
o A page dedicated to partners including (where permitted) the
names of specific disclosed partners from the world of big pharma,
biotech, academia and grants
o Enhanced links to our key social media platforms, LinkedIn and
Twitter
o An updated news section which consolidates all Company press
releases (RNS/ investor news will still be available to view
separately)
We will be monitoring usage of the enhanced website over the
next months and making further incremental updates as required.
Rebranding of printed materials will be completed over the course
of the next two months. These changes are in line with our stated
intention to enhance our marketing activities and we believe they
will improve our customer experience and help us to increase our
new business pipeline.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (nomad)
Katy Mitchell
James Sinclair-Ford
+44 (0) 161 832 2174
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is a solutions provider to the R&D
based pharmaceutical and biotechnology industry with a focus on
oncology. The Company's Virtual Tumour technology uses computer
modelling to predict the effects of cancer drugs and treatments to
improve the success rate of drug discovery and development projects
while reducing time and cost. The predictive capability of Virtual
Tumour has been confirmed by over 70 projects, involving over 30
targets and 60 drugs, and has worked with clients such as Merck
KGaA, Merck & Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 120 years collectively of working in
oncology and/or computational biology and over 120 publications in
peer reviewed journals.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCJFMMTMBJTBJL
(END) Dow Jones Newswires
March 26, 2019 09:00 ET (13:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024